‘Status Update’ Content Creator Podcast Launched by Disrupt
20. September 2023 10:40 ET
|
Disrupt
LONDON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Former award-winning Made in Chelsea star Stevie Johnson is to host a new podcast series which delves into the careers of inspirational content creators to...
Award-Winning Disrupt Wins Wizz Air as Latest High Profile Client
05. September 2023 04:00 ET
|
Disrupt
LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- High-flying influencer marketing agency, Disrupt, has been selected by Wizz Air, Europe's fastest growing and the world’s most environmentally sustainable...
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase
19. Dezember 2022 16:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update
15. November 2021 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
14. Mai 2021 07:30 ET
|
ContraFect Corporation
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase...
ContraFect Corporation Announces Proposed Public Offering of Common Stock
17. März 2021 16:01 ET
|
ContraFect Corporation
YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook
11. März 2021 16:05 ET
|
ContraFect Corporation
BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections Results from the Phase 3 DISRUPT study interim...
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
14. August 2020 07:30 ET
|
ContraFect Corporation
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering,...
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
17. Juni 2020 07:30 ET
|
ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors
15. Juni 2020 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...